Dermata Therapeutics, Inc.
Dermata Therapeutics, Inc.
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Financial Statements
Values in Millions ($) | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Financial statements beyond 3 years are for subscribers only. Unlock 17+ years of income statements, balance sheets, and cash flow statements Start 7-day free trial |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash And Cash Equivalents At Carrying Value | 4 | 7 | 8 | 5 | 6 | 10 | 3 | 6 | 5 | 5 | 7 | 7 | |||||
Prepaid Expense And Other Assets Current | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | |||||
Inventory Net | 0 | 0 | - | - | - | - | - | - | - | - | - | - | |||||
Assets | 5 | 7 | 8 | 5 | 7 | 10 | 4 | 7 | 5 | 5 | 8 | 7 | |||||
Liabilities And Stockhold… | |||||||||||||||||
Accounts Payable Current | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | |||||
Accrued Liabilities And Other Liabilities | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | - | |||||
Liabilities | 2 | 1 | 2 | 1 | 1 | 3 | 2 | 2 | 2 | 1 | 2 | 1 | |||||
Commitments And Contingen… | |||||||||||||||||
Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Stockholders Equity | |||||||||||||||||
Stockholders Equity | 3 | 6 | 6 | 4 | 6 | 7 | 2 | 5 | 3 | 4 | 6 | 6 | |||||
Additional Paid In Capital | 82 | 81 | 79 | 75 | 75 | 75 | 67 | 67 | 63 | 60 | 60 | 58 | |||||
Retained Earnings Accumulated Deficit | -78 | -75 | -73 | -71 | -70 | -68 | -66 | -63 | -59 | -57 | -53 | -51 | |||||
Liabilities And Stockholders Equity | 5 | 7 | 8 | 5 | 7 | 10 | 4 | 7 | 5 | 5 | 8 | 7 | |||||
Other Accrued Liabilities Current | 0 | 0 | 0 | 0 | - | - | 0 | - | - | - | - | 0 | |||||
Common Stock Par Or Stated Value Per Share | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Preferred Stock Par Or Stated Value Per Share | - | 0 | - | 0 | - | - | - | - | - | - | - | - | |||||
Common Stock Shares Authorized | 250 | 250 | 250 | 250 | 250 | 250 | 250 | 250 | 250 | 250 | 250 | 250 | |||||
Preferred Stock Shares Authorized | - | 10 | - | 10 | - | - | - | - | - | - | - | - | |||||
Common Stock Shares Issued | 4 | 4 | 3 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | |||||
Shares Outstanding | 4 | 4 | 3 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | |||||
Preferred Stock Shares Issued | - | 0 | - | 0 | - | - | - | - | - | - | - | - | |||||
Preferred Stock Shares Outstanding | - | 0 | - | 0 | - | - | - | - | - | - | - | - | |||||
Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables
Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables
Custom Table
Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals
Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals
Interactive Financial Visualizations
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Earnings Market Reaction
| Fiscal Year | Q1 1 Month | Q1 2 Month | Q1 3 Month | Q2 1 Month | Q2 2 Month | Q2 3 Month | Q3 1 Month | Q3 2 Month | Q3 3 Month | Q4 1 Month | Q4 2 Month | Q4 3 Month |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -0.84% | 12.61% | -1.68% | - | - | - | - | - | - | - | - | - |
| 2025 | -4.36% | -14.76% | -17.20% | -18.43% | -24.59% | -46.94% | -8.79% | -28.99% | -26.71% | -0.73% | -13.14% | -13.87% |
| 2024 | -33.33% | -52.32% | -34.95% | -25.32% | -33.05% | -36.05% | 17.07% | 16.26% | 0.00% | -30.94% | -30.77% | -36.32% |
| 2023 | - | - | - | - | - | - | -4.35% | -21.99% | -33.50% | 2.75% | -10.25% | -45.00% |
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial | ||||||||||||
Subscribe to unlock 17+ years of financial data and 90+ calculated metrics
Subscribe to unlock 17+ years of data and 90+ calculated metrics
Performance and Valuation Metrics
Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Insider Transactions
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Institutional Ownership
Dermata Therapeutics, Inc. (DRMA) — SEC Financial Statements & Analysis
Dermata Therapeutics, Inc. (DRMA) is a pharmaceutical preparations company, incorporated in DE. Dermata Therapeutics, Inc. trades on Nasdaq as: DRMA, DRMAW. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), Dermata Therapeutics, Inc. reported a Price-to-Book (P/B) ratio of 1.49x (TTM), at a market cap of $5.19M. Figures below are sourced from SEC EDGAR, as-filed.
- P/B TTM
- 1.49x
- Market Cap
- $5.19M
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Dermata Therapeutics, Inc. in?
Dermata Therapeutics, Inc. (DRMA) operates in the Pharmaceutical Preparations industry.
What is DRMA's market cap?
Dermata Therapeutics, Inc. (DRMA) has a market capitalization of $5.19M as of 2026-06-30.
What exchange does DRMA trade on?
Dermata Therapeutics, Inc. (DRMA) trades on the Nasdaq.
Where is Dermata Therapeutics, Inc. incorporated?
Dermata Therapeutics, Inc. is incorporated in DE.